Published in Women's Health Weekly, May 20th, 2004
The total net loss for the quarter was $5.8 million, compared with a net loss of $2.8 million for the same period in 2003.
Research and development expenses increased 105% to $4.3 million for the first quarter of 2004 from $2.1 million for the first quarter of 2003. This increase was mainly attributable to planned expenditures related to the pivotal phase III clinical trial of ACAPODENE (Toremifene Citrate) tablets for the treatment of side...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.